The generic version of Novo Nordisk’s Victoza is indicated for treating Type 2 diabetes in adults, adolescents, and children aged 10 and above, as an add-on to diet and exercise.
The approval was granted by India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), under the recently introduced 101 route — which allows for faster approval based on prior clearances from globally recognised regulators.
“This is another significant step forward in expanding access to GLP-1 therapies in India,” said Siddharth Mittal, CEO and MD of Biocon. “With over 77 million people living with diabetes in India, this approval enables us to address a critical unmet need.”
Also read: Biocon gets six-month extension on insulin supply contract In Malaysia
Glucagon-like peptide-1 (GLP-1) drugs help lower blood sugar and aid weight loss by enhancing insulin release, suppressing glucagon, and slowing digestion, making them effective for managing Type 2 diabetes.
Biocon said it is preparing to launch the product in India through commercialisation partners. Shares of Biocon ended 0.54% lower at ₹333.75 on the BSE ahead of the announcement.
